Immix Biopharma, Inc. IMMX Deferred Tax Assets
Deferred Tax Assets at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost.
The official record: Immix Biopharma, Inc.’s 10-K/A, filed March 27, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s deferred tax assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s deferred tax assets?
- Immix Biopharma, Inc. (IMMX) reported deferred tax assets of $1.13M in Q4 2025.
- How has Immix Biopharma, Inc.'s deferred tax assets changed year-over-year?
- Immix Biopharma, Inc.'s deferred tax assets increased by 45.5% year-over-year, from $775.25K to $1.13M.
- What is the long-term trend for Immix Biopharma, Inc.'s deferred tax assets?
- Over 5 years (2020 to 2025), Immix Biopharma, Inc.'s deferred tax assets has grown at a 91.6% compound annual growth rate (CAGR), from $43.64K to $1.13M.
- What does deferred tax assets mean?
- Future tax benefits from temporary differences, net operating loss carryforwards, and tax credit carryforwards that will reduce future tax payments.